BioCytics Secures Significant G-Rex Grant to Combat Cancer
BioCytics is excited to announce that the company has been awarded a G-Rex grant worth $100,000 from ScaleReady. This grant aims to support BioCytics' research and development endeavors in creating a cutting-edge, cGMP G-Rex-based manufacturing process targeted at producing immune cell fractions. These fractions play a vital role in BioCytics' innovative platform therapy designed specifically for treating tumors.
The Significance of the G-Rex Grant
The G-Rex Grant is part of a broader $20 million initiative led by ScaleReady, showcasing their commitment to advancing Cell and Gene Therapy (CGT) development and manufacturing capabilities. This grant not only provides financial resources but also significant support for accelerating the optimization of cell manufacturing processes.
BioCytics' Approach to Cancer Therapy
BioCytics’ therapy involves a sophisticated method of isolating, expanding, and activating specific immune cell fractions from a patient's body, fostering a personalized approach to battling cancer. This technology is crucial in empowering the immune system to effectively combat tumors and enhance patient outcomes.
Dr. Renaud Warin, the Chief Scientific Officer of BioCytics, expressed confidence in the power of this grant by stating, "The grant award will allow us to accelerate the development of our IND-bound immune fraction BCyIF1 against solid tumors. Through this award, we will gain access to ScaleReady's extensive range of products and expertise." This collaboration stands to enrich BioCytics’ innovative technologies significantly.
Collaboration with ScaleReady: A Win-Win Situation
Josh Ludwig, the Commercial Director of ScaleReady, emphasized the importance of collaboration in furthering the field of cell and gene therapy, saying, "This is yet another example of how ScaleReady is willing and able to go beyond the traditional business model. We are eager to assist BioCytics in bringing novel, affordable immune cell cancer therapies directly to patients through Point-of-Care manufacturing." This synergy is expected to lead to groundbreaking advancements in the treatment of cancer.
About BioCytics, Inc.
Established in 2005, BioCytics, Inc. is a privately held health technology company based in North Carolina, adjacent to the Carolina BioOncology Institute, which specializes in cancer treatment and clinical trials. The company focuses on Autologous Adaptive Cell Therapy (AACT) to cultivate an immuno-oncology platform that utilizes patients' own immune cells for treating solid tumors. This revolutionary point-of-care cell manufacturing process is designed to produce non-genetically modified effector cell fractions suitable for various stages of solid tumors.
About ScaleReady
ScaleReady has positioned itself at the forefront of cell and gene-modified cell therapy. It provides an innovative G-Rex-centric manufacturing platform enabling flexible, scalable, and affordable development of CGT drug products. Notably, the G-Rex platform serves over 800 organizations, significantly contributing to approximately 50% of CGT clinical trials and supporting the production of five commercially approved CGT drugs, marking its prominence in the clinical landscape.
Frequently Asked Questions
What is the purpose of the G-Rex grant awarded to BioCytics?
The G-Rex grant aims to support BioCytics in optimizing their manufacturing process for immune cell fractions used in cancer therapies.
How does BioCytics’ therapy work?
BioCytics' therapy isolates, expands, and activates a patient's immune cells to enhance the body's natural ability to fight cancer.
Who is ScaleReady and what role do they play in this grant?
ScaleReady is an organization that provides advanced manufacturing platforms for cell and gene therapies and awarded the G-Rex grant to support BioCytics' research.
What are the future implications of this grant for cancer treatment?
This grant could significantly boost the development of innovative cancer therapies, making them more accessible and effective for patients.
How can one learn more about BioCytics and their technologies?
For more information, you can visit BioCytics’ website and follow their updates on social media.
